Exubera:Is inhaled insulin finally within reach?

The Food & Drug Administration has accepted Pfizer and Sanofi-Aventis' new drug application for Exubera (inhaled human insulin powder). For the past 80 years subcutaneous injection has been the only route for delivering insulin to patients with diabetes mellitus, which affects over 17 million people in the United States. Insulin therapy is required for patients with Type 1 diabetes, and many patients with Type 2 diabetes will require insulin therapy either alone or as an adjunct to their oral medications. Lack of acceptance of continuous subcutaneous insulin delivery or multiple daily injections have been barriers to obtaining optimal HbA1c levels.

View Full Article